Clinical Trial Update: Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial investigating 18F-DCFPyL PET/CT imaging for prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-DCFPyL (DCFPyL radiotracer for PSMA imaging)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: WITHDRAWN